• 목록
• 답변
• 글쓰기
• 게시판 리스트 옵션
  • 수정
  • 삭제

Personalized Depression Treatment

Traditional therapies and medications are not effective for a lot of people suffering from depression. The individual approach to treatment refractory depression could be the answer.

Cue is an intervention platform that converts sensors that are passively gathered from smartphones into personalised micro-interventions for improving mental health. We analyzed the most effective-fit personal ML models for each subject using Shapley values to understand their predictors of feature and reveal distinct characteristics that can be used to predict changes in mood as time passes.

Predictors of Mood

Depression is a major cause of mental illness around the world.1 Yet, only half of those with the condition receive treatment. To improve the outcomes, doctors must be able to recognize and treat patients with the highest probability of responding to specific treatments.

A customized depression treatment is one method to achieve this. By using sensors on mobile phones as well as an artificial intelligence voice assistant, and other digital tools researchers at the University of Illinois Chicago (UIC) are developing new methods to determine which patients will benefit from which treatments. Two grants worth more than $10 million will be used to discover biological and behavior predictors of response.

So far, the majority of research on predictors for depression treatment effectiveness has centered on sociodemographic and clinical characteristics. These include demographics like age, gender, and education, as well as clinical aspects such as symptom severity, comorbidities and biological markers.

Few studies have used longitudinal data in order to predict mood in individuals. A few studies also take into account the fact that moods can vary significantly between individuals. Therefore, it is essential to create methods that allow the identification of different mood predictors for each person and the effects of treatment.

The team's new approach uses daily, in-person evaluations of mood and lifestyle variables using a smartphone app called AWARE, a cognitive evaluation with the BiAffect app and electroencephalography -- an imaging technique that monitors brain activity. This enables the team to develop algorithms that can detect various patterns of behavior and emotions that are different between people.

In addition to these methods, the team developed a machine-learning algorithm to model the dynamic predictors of each person's depressed mood. The algorithm combines these individual variations into a distinct "digital phenotype" for each participant.

This digital phenotype has been linked to CAT DI scores, a psychometrically validated symptom severity scale. However, the correlation was weak (Pearson's r = 0.08, adjusted BH-adjusted P-value of 3.55 1003) and varied widely across individuals.

Predictors of Symptoms

Depression is among the leading causes of disability1 but is often not properly diagnosed and treated. Depressive disorders are often not treated due to the stigma attached to them, as well as the lack of effective treatments.

To facilitate personalized treatment to improve treatment, identifying the factors that predict the severity of symptoms is crucial. The current methods for predicting symptoms rely heavily on clinical interviews, which are unreliable and only identify a handful of characteristics that are associated with depression.

Machine learning can increase the accuracy of the diagnosis and treatment of depression by combining continuous digital behavior phenotypes gathered from smartphones with a validated mental health tracker online (the Computerized Adaptive Testing Depression Inventory CAT-DI). These digital phenotypes capture a large number of distinct behaviors and activities that are difficult to document through interviews, and also allow for continuous and high-resolution measurements.

The study comprised University of California Los Angeles students with mild to severe depression symptoms who were participating in the Screening and Treatment for Anxiety and Depression program29 that was developed as part of the UCLA Depression Grand Challenge. Participants were directed to online assistance or in-person clinics in accordance with their severity of depression. Those with a score on the CAT-DI of 35 or 65 students were assigned online support with the help of a coach. Those with scores of 75 patients were referred to in-person clinical care for psychotherapy.

Participants were asked a set of questions at the beginning of the study regarding their psychosocial and demographic characteristics as well as their socioeconomic status. These included age, sex, education, work, and financial situation; whether they were divorced, married or single; the frequency of suicidal ideas, intent or attempts; and the frequency with that they consumed alcohol. Participants also scored their level of depression symptom severity on a scale ranging from 0-100 using the CAT-DI. CAT-DI assessments were conducted each other week for the participants who received online support and once a week for those receiving in-person support.

Predictors of Treatment Response

Research is focusing on personalization of treatment for depression. Many studies are focused on finding predictors that can aid clinicians in identifying the most effective drugs to treat each patient. Pharmacogenetics in particular uncovers genetic variations that affect how the human body metabolizes drugs. This lets doctors select the medication that will likely work best for every patient, minimizing time and effort spent on trial-and-error treatments and avoid any negative side consequences.

Another approach that is promising is to build models for prediction using multiple data sources, combining clinical information and neural imaging data. These models can be used to determine the variables that are most predictive of a specific outcome, like whether a drug will help with symptoms or mood. These models can also be used to predict the patient's response to treatment that is already in place which allows doctors to maximize the effectiveness of treatment currently being administered.

A new generation employs machine learning techniques like supervised and classification algorithms such as regularized logistic regression, and tree-based methods to combine the effects of several variables and increase the accuracy of predictions. These models have proven to be useful for the prediction of treatment outcomes like the response to antidepressants. These techniques are becoming increasingly popular in psychiatry and will likely become the norm in the future Medical Treatment For Depression (Https://Valetinowiki.Racing/) practice.

In addition to the ML-based prediction models research into the mechanisms behind depression continues. Recent research suggests that the disorder is associated with neurodegeneration in particular circuits. This theory suggests that an individualized treatment for depression will be based on targeted therapies that restore normal functioning to these circuits.

Internet-delivered interventions can be an effective method to achieve this. They can offer an individualized and tailored experience for patients. One study found that a program on the internet was more effective than standard care in reducing symptoms and ensuring the best quality of life for people with MDD. A controlled study that was randomized to a personalized treatment for depression showed that a substantial percentage of patients experienced sustained improvement and had fewer adverse consequences.

Predictors of Side Effects

A major obstacle in individualized depression treatment is predicting the antidepressant medications that will have very little or no side effects. Many patients have a trial-and error approach, using various medications being prescribed before settling on one that is effective and tolerable. Pharmacogenetics offers a fresh and exciting way to select antidepressant medicines that are more effective and precise.

There are many predictors that can be used to determine which antidepressant should be prescribed, such as gene variations, patient phenotypes such as ethnicity or gender and the presence of comorbidities. However finding the most reliable and reliable factors that can predict the effectiveness of a particular treatment is likely to require controlled, randomized trials with significantly larger numbers of participants than those that are typically part of clinical trials. This is due to the fact that it can be more difficult to detect interactions or moderators in trials that only include a single episode per person instead of multiple episodes over a long period of time.

Additionally the prediction of a patient's reaction to a particular medication is likely to require information about comorbidities and symptom profiles, and the patient's previous experience with tolerability and efficacy. Currently, only a few easily assessable sociodemographic variables and clinical variables appear to be reliably related to response to MDD. These include gender, age, race/ethnicity, BMI, SES and the presence of alexithymia.

The application of pharmacogenetics to treatment for depression is in its beginning stages and there are many obstacles to overcome. First, it is important to be able to comprehend and understand the definition of the genetic factors that cause depression, and an accurate definition of an accurate predictor of treatment response. Ethics like privacy, and the responsible use genetic information must also be considered. In the long run the use of pharmacogenetics could be a way to lessen the stigma associated with mental health treatment and improve the outcomes of those suffering with depression. Like any other psychiatric treatment it is essential to carefully consider and implement the plan. For now, the best option is to provide patients with an array of effective depression medications and encourage them to speak freely with their doctors about their experiences and concerns.